At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD
In Brief
A Phase 2 clinical trial evaluating Placebo and GSK233705/GW642444 for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 61 participants across 12 sites.
Detailed Summary
The purpose of this study is the evaluate the safety and tolerability of repeat dosing of the combination of inhaled GSK233705 and GW642444 administered once-daily in subjects with COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartNov 2008
Primary CompletionFeb 2009
TodayJul 2026
First PostedSep 9, 2008
Enrollment StartNov 13, 2008
Primary CompletionFeb 12, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.8 years ago
Interventions
Placebodrug
matching placebo
GSK233705/GW642444drug
The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.